In Q3 FY2026 (ended January 31, 2026), Kestra Medical Technologies reported revenue of $24.6 million, up 62.7% year-over-year. Net loss widened to $34.2 million from $21.5 million, and operating loss increased to $34.8 million. Diluted EPS was -$0.61, improving 51.2% from -$1.25 a year ago.
•Revenue grew 62.7% YoY to $24.6 million.
•Net loss increased 58.8% to $34.2 million.
•Operating loss rose 68.8% to $34.8 million.
•Diluted EPS improved to -$0.61 from -$1.25.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Kestra Medical Technologies is a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest
A suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. Founded in 2014, the company is based in Kirkland, Washington.
Kestra Medical Technologies is a wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease. The company develops and commercializes the Cardiac Recovery System platform, which integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its primary product is the ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest. Additionally, Kestra offers a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight, with the objective of improving patient outcomes. The company's technologies are designed to be intuitive, intelligent, and connected.
On which stock exchange is Kestra Medical Technologies (KMTS) listed and what currency is used?
Kestra Medical Technologies is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KMTS. The trading currency for its shares is the US Dollar (USD). As a US-based company, it is traded on a major American exchange, providing liquidity and visibility to investors in the United States and globally.
What sector and industry does Kestra Medical Technologies (KMTS) operate in?
Kestra Medical Technologies operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This industry encompasses companies that manufacture and distribute medical devices, instruments, and supplies used in healthcare settings. Kestra's focus on wearable cardioverter defibrillators and digital health solutions places it at the intersection of medical devices and digital healthcare, addressing cardiovascular disease management.
Where is Kestra Medical Technologies (KMTS) headquartered and what markets does it serve?
Kestra Medical Technologies is headquartered in Kirkland, Washington, United States. The company primarily serves the US market, as indicated by its region designation 'us'. Its products and services are designed for patients at elevated risk of sudden cardiac arrest, and it works with healthcare providers to improve patient outcomes through its Cardiac Recovery System platform and ASSURE WCD device.
When was Kestra Medical Technologies (KMTS) founded?
Kestra Medical Technologies was founded in 2014. Since its founding, the company has focused on developing innovative wearable medical devices and digital healthcare solutions for cardiovascular disease. Its headquarters in Kirkland, Washington, has been the base for its research, development, and commercialization efforts over the years.